BRAF and melanoma: No statistically significant difference was seen between the genotypes and other clinical characteristics, such as M stage and LDH levels.Seeing that B-RAF inhibitors can affect survival in patients with B-RAF mutant melanomas, this group of patients was removed from the survival analysis.